Augurex

Augurex has developed a rheumatoid arthritis diagnostic blood test which will be launched in the US in 2013 by Quest Diagnostics.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Canada
  • Currency USD
  • Founded October 2007
  • Employees 5
  • Website augurex.com

Company Summary

The early diagnosis and treatment of rheumatoid arthritis (RA) is critical to improve patient outcomes. RA is a chronic, debilitating auto-immune condition that affects 1.5% of the population. Doctors, patients and insurance companies alike will benefit from the clinical use of the Augurex blood test since it will improve patient quality of life and diminish the economic burden of this disease through early diagnosis.

Team

  • Norma K Biln
    Chief Executive Officer

    Norma has 20 years of experience in the life sciences sector having worked in the pharmaceutical industry as well as within BC biotechnology companies before she co-founded Augurex. She has a BSc and MBA, sits on the Board of BioTalent Canada and is jury member of the New Ventures BC Competition. As Augurex's CEO, Norma is focused on achieving clear value-creating milestones towards an exit that maximizes the return to shareholders.

  • Anthony Marotta
    Chief Scientific Officer

    Anthony holds a PhD in experimental medicine and leads the science at Augurex. His creativity and business acumen set him apart from most scientific leaders. Anthony has worked in the life sciences space for 20 years and has consistently created progressive opportunities that have delivered great returns for companies that he has been involved with.

  • Norma Biln

Advisors

  • McCarthy Tetrault and Arnold & Porter
    Lawyer
    Unconfirmed
    Ernst & Young
    Accountant
    Unconfirmed

Previous Investors

  • Accredited Individual Investors
    Unconfirmed
    WUTIF
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free